Skip to main content
. 2012 Mar 27;13:15. doi: 10.1186/1471-2369-13-15

Table 3.

Effects of hypertonic saline infusion (3%, 7 ml kg-1) on UNa, FENa, and u-ENaC β-CR in 21 patients with essential hypertension and 20 normotensive controls during high and low sodium intake

Baseline 60 Min 120 Min 180 Min PGLM RM
UNa (μmol min-1)

HS Patients 343 (300; 386)§ 615 (499; 731)† 700 (581; 819)† 541 (471; 611)† P = 0.110

Controls 323 (285; 361)§ 497 (321; 672)† 499 (357; 642)† 460 (366; 554)†

LS Patients 91 (57; 125) 254 (168; 340)† 275 (192; 357)† 277 (211; 343)† P = 0.164

Controls 57 (40; 74) 175 (62; 288)† 191 (99; 282)† 181 (123; 239)†

FENa (%)

HS Patients 2.66 (2.34; 2.98)§ 5.10 (4.20; 6.00)† 5.35 (4.46; 6.24)† 4.57 (3.96; 5.19)† P = 0.030

Controls 2.51 (2.10; 2.92)§ 3.73 (2.61; 4.86)† 3.72 (2.76; 4.68)† 3.49 (2.85; 4.14)†

LS Patients 0.75 (0.49; 1.01) 2.24 (1.55; 2.93)† 2.29 (1.69; 2.90)† 2.28 (1.84; 2.72)† P = 0.059

Controls 0.49 (0.34; 0.65) 1.34 (0.67; 2.01)† 1.52 (0.90; 2.15)† 1.44 (1.06; 1.82)†

u-EnaCβ-CR (pg μmol-1)

HS Patients 11.4 (10.2; 12.7)§ 10.4 (9.4; 11.3) 10.8 (9.6; 12.1) 11.1 (9.6; 12.6) P = 0.796

Controls 11.2 (9.9; 12.5) 10.8 (9.7; 12.0) 12.2 (10.7; 13.8)† 11.0 (9.4; 12.6)

LS Patients 10.4 (9.4; 11.3) 10.7 (9.3; 12.2) 11.5 (10.4; 12.6)† 10.9 (10.0; 11.9) P = 0.716

Controls 11.5 (9.8; 13.2) 11.2 (10.0; 12.4) 12.4 (11.3; 13.6)† 11.9 (10.2; 13.5)

Values are means with 95% confidence intervals in brackets. UNa, urinary sodium excretion rate; FENa, fractional sodium excretion; u-ENaCβ-CR, urinary ENaCβ excretion corrected for creatinine. PGLM RM: patients compared with controls, GLM repeated measures with time as within-subject factor and blood pressure as between-subject factor. * P < 0.05, baseline patients vs. controls, Student's t-test. § P < 0.05, baseline HS vs. LS, paired samples t-test. † P < 0.05, compared with baseline, paired samples t-test